Abstract
Background: Intracerebral hemorrhage (ICH) is one of the most common subtypes of stroke.
Objectives: This study aimed to investigate the mechanism of Astragaloside IV (AS-IV) on inflammatory injury after ICH.
Methods: The ICH model was established by the injection of collagenase and treated with ASIV (20 mg/kg or 40 mg/kg). The neurological function, water content of the bilateral cerebral hemisphere and cerebellum, and pathological changes in brain tissue were assessed. The levels of interleukin-1 beta (IL-1β), IL-18, tumor necrosis factor-alpha, interferon-gamma, and IL-10 were detected by enzyme-linked immunosorbent assay. The levels of Kruppel-like factor 2 (KLF2), NOD-like receptor family pyrin domain containing 3 (NLRP3), GSDMD-N, and cleaved-caspase-1 were detected by reverse transcription-quantitative polymerase chain reaction and Western blot assay. The binding relationship between KLF2 and NLRP3 was verified by chromatin-immunoprecipitation and dual-luciferase assays. KLF2 inhibition or NLRP3 overexpression was achieved in mice to observe pathological changes.
Results: The decreased neurological function, increased water content, severe pathological damage, and inflammatory response were observed in mice after ICH, with increased levels of NLRP3/GSDMD-N/cleaved-caspase-1/IL-1β/IL-18 and poorly-expressed KLF2 in brain tissue. After AS-IV treatment, the neurological dysfunction, high brain water content, inflammatory response, and pyroptosis were alleviated, while KLF2 expression was increased. KLF2 bonded to the NLRP3 promoter region and inhibited its transcription. Down-regulation of KLF2 or upregulation of NLRP3 reversed the effect of AS-IV on inhibiting pyroptosis and reducing inflammatory injury in mice after ICH.
Conclusion: AS-IV inhibited NLRP3-mediated pyroptosis by promoting KLF2 expression and alleviated inflammatory injury in mice after ICH.
Keywords: KLF2, NLRP3, Intracerebral hemorrhage, astragaloside IV, pyroptosis, inflammatory injury, the promoter, hematoxylin and eosin.
[http://dx.doi.org/10.1016/j.neuropharm.2017.09.033] [PMID: 28947377]
[http://dx.doi.org/10.5853/jos.2019.02236] [PMID: 32027790]
[http://dx.doi.org/10.3390/genes13071250] [PMID: 35886033]
[http://dx.doi.org/10.1016/j.jns.2019.01.013] [PMID: 30682522]
[http://dx.doi.org/10.1007/s13311-020-00902-w] [PMID: 32720246]
[http://dx.doi.org/10.1016/j.intimp.2018.12.019] [PMID: 30594776]
[http://dx.doi.org/10.3389/fimmu.2022.989503] [PMID: 36131917]
[http://dx.doi.org/10.1155/2021/1552127] [PMID: 34630845]
[http://dx.doi.org/10.3389/fphar.2015.00262] [PMID: 26594174]
[http://dx.doi.org/10.1186/s12974-017-1039-7] [PMID: 29301581]
[http://dx.doi.org/10.3389/fimmu.2022.810582] [PMID: 35154128]
[http://dx.doi.org/10.2174/1570159X20666220830115018] [PMID: 36043798]
[http://dx.doi.org/10.3389/fnins.2021.755902] [PMID: 34867166]
[http://dx.doi.org/10.3389/fphar.2021.642925] [PMID: 34349641]
[http://dx.doi.org/10.1080/21691401.2019.1687492] [PMID: 31713440]
[http://dx.doi.org/10.1016/j.taap.2018.12.002] [PMID: 30529164]
[http://dx.doi.org/10.3389/fphar.2021.639898] [PMID: 33841157]
[http://dx.doi.org/10.1016/j.wneu.2018.06.212] [PMID: 29981464]
[http://dx.doi.org/10.1016/j.bioorg.2022.105975] [PMID: 35728292]
[http://dx.doi.org/10.1080/13880209.2022.2101668] [PMID: 36121248]
[http://dx.doi.org/10.1134/S0006297920010058] [PMID: 32079517]
[http://dx.doi.org/10.1016/j.brainresbull.2021.10.018] [PMID: 34717966]
[http://dx.doi.org/10.1016/j.omtm.2021.01.015] [PMID: 34141823]
[http://dx.doi.org/10.1016/j.cellsig.2020.109843] [PMID: 33253911]
[http://dx.doi.org/10.1186/s12974-020-01853-x] [PMID: 32466767]
[PMID: 11042900]
[http://dx.doi.org/10.1002/ar.22988] [PMID: 25045138]
[http://dx.doi.org/10.1089/neu.2011.1807] [PMID: 21534727]
[http://dx.doi.org/10.1006/meth.2001.1262] [PMID: 11846609]
[http://dx.doi.org/10.1093/nar/gkab1113] [PMID: 34850907]
[http://dx.doi.org/10.1080/14737175.2019.1623671] [PMID: 31188036]
[http://dx.doi.org/10.1016/j.phymed.2021.153630] [PMID: 34217968]
[http://dx.doi.org/10.1177/17590914211010647] [PMID: 33906483]
[http://dx.doi.org/10.3389/fphar.2021.629379] [PMID: 33815110]
[http://dx.doi.org/10.1126/scitranslmed.abe9890] [PMID: 34349037]
[http://dx.doi.org/10.1186/s12974-020-1726-7] [PMID: 32019561]
[http://dx.doi.org/10.1155/2021/1020614] [PMID: 34616501]
[http://dx.doi.org/10.1177/2040622320987348] [PMID: 33948156]
[http://dx.doi.org/10.3390/ijms18112383] [PMID: 29125549]
[http://dx.doi.org/10.1038/s41420-022-00813-z] [PMID: 35091544]
[http://dx.doi.org/10.3390/ijms232113477] [PMID: 36362263]
[http://dx.doi.org/10.1161/CIRCRESAHA.118.314402] [PMID: 31318658]
[http://dx.doi.org/10.3390/biomedicines8070205] [PMID: 32664349]
[http://dx.doi.org/10.3389/fnmol.2019.00202] [PMID: 31555089]
[http://dx.doi.org/10.4103/1673-5374.346551] [PMID: 36018178]
[http://dx.doi.org/10.1155/2022/8336070] [PMID: 35509841]
[http://dx.doi.org/10.1016/j.neulet.2016.12.046] [PMID: 28011393]